{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"122-602-068-382-204","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"122-602-068-382-204"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11849,"type":"PATENT","title":"University of Liege Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":6891,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8461,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:univ* AND Liege. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1416
Search Applicants and Owners separately:univ* AND Liege. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1416
wherein R1 or R2 is hydrogen and the other of substituents R1 or R2 is selected from H and O—C1-6 alkyl;\n
wherein R3 is selected from oxazolyl, pyridyl, imidazolyl and pyrimidyl, which selection can be substituted with one R12 residue;\n
wherein R5 and R6 are independently selected from H, fluorine, chlorine and bromine;\n
R8 and R9 are H; and\n
R12 is selected from H, halogen, hydroxy, CN, C1-3 alkyl and C1-3 alkoxy; or\n
a pharmaceutically acceptable salt thereof."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein the compound is chosen from:\n
3-(6-methoxynaphthalen-2-yl)pyridine;\n
3-(6-hydroxynaphthalen-2-yl)pyridine;\n
3-(6-bromonaphthalen-2-yl)pyridine;\n
3-(6-ethoxynaphthalen-2-yl)pyridine;\n
3-(6-propoxynaphthalen-2-yl)pyridine;\n
3-(6-benzyloxynaphthalen-2-yl)pyridine;\n
3-(6-cyanonaphthalen-2-yl)pyridine;\n
3-(5-chloro-6-methoxynaphthalen-2-yl)pyridine;\n
3-(5-bromo-6-methoxynaphthalen-2-yl)pyridine;\n
3-(7-methoxynaphthalen-2-yl)pyridine; and\n
3-(1-chloro-7-methoxynaphthalen-2-yl)pyridine."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein R3 is selected from 3-pyridyl, 4-pyridyl, 1-imidazolyl, 4-imidazolyl, and 5-pyrimidyl."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein R3 is 3-pyridyl."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating hyperaldosteronism, heart failure, myocardial fibrosis, hypercortisolism, diabetes mellitus, depression, age-related cognitive decline or metabolic syndrome in a patient comprising, administering to said patient a therapeutically effective amount of a compound selected from:\n
3-(1,5-dichloro-6-methoxynaphthalen-2-yl)pyridine;\n
3-(3-methoxynaphthalen-2-yl)pyridine;\n
methyl 6-(pyridin-3-yl)-2-naphthoate;\n
6-(pyridin-3-yl)-2-naphthamide; and\n
N-methyl-6-(pyridin-3-yl)-2-naphthamide."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising a compound having a structure of formula (Ia)\n
wherein R1 or R2 is hydrogen and the other of substituents R1 or R2 is O—C1-6 alkyl;\n
wherein R3 is selected from oxazolyl, pyridyl, imidazolyl and pyrimidyl, which selection can be substituted with one R12 residue;\n
wherein R5 and R6 are independently selected from H, fluorine, chlorine and bromine;\n
R8 and R9 are H; and\n
R12 is selected from H, halogen, hydroxy, CN, C1-3 alkyl and C1-3 alkoxy;\n
or a pharmaceutically acceptable salt thereof."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The composition according to claim 6, wherein R3 is selected from 3-pyridyl, 4-pyridyl, 1-imidazolyl, 4-imidazolyl, and 5-pyrimidyl."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The composition according to claim 7, wherein R3 is 3-pyridyl."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The composition according to claim 6, wherein the compound is selected from:\n
3-(6-methoxynaphthalen-2-yl)pyridine;\n
3-(6-hydroxynaphthalen-2-yl)pyridine;\n
3-(6-bromonaphthalen-2-yl)pyridine;\n
3-(6-ethoxynaphthalen-2-yl)pyridine;\n
3-(6-propoxynaphthalen-2-yl)pyridine;\n
3-(6-benzyloxynaphthalen-2-yl)pyridine;\n
3-(5-chloro-6-methoxynaphthalen-2-yl)pyridine;\n
3-(5-bromo-6-methoxynaphthalen-2-yl)pyridine;\n
3-(1,5-dichloro-6-methoxynaphthalen-2-yl)pyridine;\n
3-(7-methoxynaphthalen-2-yl)pyridine; and\n
3-(1-chloro-7-methoxynaphthalen-2-yl)pyridine."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition for treating hyperaldosteronism, heart failure, myocardial fibrosis, hypercortisolism, diabetes mellitus, depression, age-related cognitive decline and metabolic syndrome, comprising one or more compounds having a structure of formula (Ia)\n
wherein R1 or R2 is hydrogen and the other of substituents R1 or R2 is O—C1-6 alkyl;\n
wherein R3 is selected from oxazolyl, pyridyl, imidazolyl and pyrimidyl, which selection can be substituted with one R12 residue;\n
wherein R5 and R6 are independently selected from H, fluorine, chlorine and bromine;\n
R8 and R9 are H; and\n
R12 is selected from H, halogen, hydroxy, CN, C1-3 alkyl and C1-3 alkoxy;\n
or a pharmaceutically acceptable salt thereof."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A composition according to claim 10, wherein R3 is selected from oxazolyl, pyridyl, imidazolyl, and pyrimidyl; wherein R5 and R6 are each independently selected from H, fluorine, chlorine, or bromine; and wherein R4, R8, and R9 are H."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The composition according to claim 11, wherein R3 is selected from 3-pyridyl, 4-pyridyl, 1-imidazolyl, 4-imidazolyl, and 5-pyrimidyl."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The composition according to claim 12, wherein R3 is 3-pyridyl."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The composition according to claim 10, wherein the compound is selected from:\n
3-(6-methoxynaphthalen-2-yl)pyridine;\n
3-(6-bromonaphthalen-2-yl)pyridine;\n
3-(6-ethoxynaphthalen-2-yl)pyridine;\n
3-(6-propoxynaphthalen-2-yl)pyridine;\n
3-(6-benzyloxynaphthalen-2-yl)pyridine;\n
3-(5-chloro-6-methoxynaphthalen-2-yl)pyridine;\n
3-(5-bromo-6-methoxynaphthalen-2-yl)pyridine;\n
3-(1,5-dichloro-6-methoxynaphthalen-2-yl)pyridine;\n
3-(7-methoxynaphthalen-2-yl)pyridine; and\n
3-(1-chloro-7-methoxynaphthalen-2-yl)pyridine."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The composition according to claim 10, further comprising an additional pharmacologically active compound."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A compound having the formula (Ia)\n
wherein R1 or R2 is hydrogen and the other of substituents R1 or R2 is —O—C1-6 alkyl;\n
wherein R3 is selected from oxazolyl, pyridyl, and imidazolyl, which selection can be substituted with one R12 residue;\n
wherein R5 and R6 are independently selected from H, fluorine, chlorine and bromine;\n
R8 and R9 are H; and\n
R12 is selected from H, halogen, hydroxy, CN, C1-3 alkyl and C1-3 alkoxy;\n
or a pharmaceutically acceptable salt thereof."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The compound according to claim 16, wherein R3 is selected from 3-pyridyl, 1-imidazolyl, and 4-imidazolyl."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The compound according to claim 17, wherein R3 is 3-pyridyl."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The compound according to claim 16, wherein the compound is selected from:\n
3-(6-methoxynaphthalen-2-yl)pyridine;\n
3-(6-bromonaphthalen-2-yl)pyridine;\n
3-(6-ethoxynaphthalen-2-yl)pyridine;\n
3-(6-propoxynaphthalen-2-yl)pyridine;\n
3-(6-benzyloxynaphthalen-2-yl)pyridine;\n
3-(5-chloro-6-methoxynaphthalen-2-yl)pyridine;\n
3-(5-bromo-6-methoxynaphthalen-2-yl)pyridine;\n
3-(1,5-dichloro-6-methoxynaphthalen-2-yl)pyridine;\n
3-(7-methoxynaphthalen-2-yl)pyridine; and\n
3-(1-chloro-7-methoxynaphthalen-2-yl)pyridine."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["A method of selectively inhibiting aldosterone synthase or steroid 11β-hydroxylase comprising, administering to a human a compound having a structure of formula (Ia)\n
wherein R1 or R2 is hydrogen and the other of substituents R1 or R2 is selected from H and O—C1-6 alkyl;\n
wherein R3 is selected from oxazolyl, pyridyl, imidazolyl and pyrimidyl, which selection can be substituted with one R12 residue;\n
wherein R5 and R6 are independently selected from H, fluorine, chlorine and bromine;\n
R8 and R9 are H;\n
and R12 is selected from H, halogen, hydroxy, CN, C1-3 alkyl and C1-3 alkoxy;\n
or a pharmaceutically acceptable salt thereof."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 20, wherein the compound is chosen from:\n
3-(6-methoxynaphthalen-2-yl)pyridine;\n
3-(6-hydroxynaphthalen-2-yl)pyridine;\n
3-(6-bromonaphthalen-2-yl)pyridine;\n
3-(6-ethoxynaphthalen-2-yl)pyridine;\n
3-(6-propoxynaphthalen-2-yl)pyridine;\n
3-(6-benzyloxynaphthalen-2-yl)pyridine;\n
3-(6-cyanonaphthalen-2-yl)pyridine;\n
3-(5-chloro-6-methoxynaphthalen-2-yl)pyridine;\n
3-(5-bromo-6-methoxynaphthalen-2-yl)pyridine;\n
3-(1,5-dichloro-6-methoxynaphthalen-2-yl)pyridine;\n
3-(7-methoxynaphthalen-2-yl)pyridine; and\n
3-(1-chloro-7-methoxynaphthalen-2-yl)pyridine."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 20, wherein R3 is selected from 3-pyridyl, 4-pyridyl, 1-imidazolyl, 4-imidazolyl, and 5-pyrimidyl."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 20, wherein R3 is 3-pyridyl."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition comprising a compound selected from:\n
3-(6-cyanonaphthalen-2-yl)pyridine;\n
3-[5-(pyridin-3-yl)-6-methoxynaphthalen-2-yl]pyridine;\n
3-(3-methoxynaphthalen-2-yl)pyridine;\n
methyl 6-(pyridin-3-yl)-2-naphthoate;\n
6-(pyridin-3-yl)-2-naphthamide; and\n
N-methyl-6-(pyridin-3-yl)-2-naphthamide."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["A method of selectively inhibiting aldosterone synthase or steroid 11β-hydroxylase comprising, administering to a human a compound selected from:\n
3-(1,5-dichloro-6-methoxynaphthalen-2-yl)pyridine;\n
3-(3-methoxynaphthalen-2-yl)pyridine;\n
methyl 6-(pyridin-3-yl)-2-naphthoate;\n
6-(pyridin-3-yl)-2-naphthamide; and\n
N-methyl-6-(pyridin-3-yl)-2-naphthamide."],"number":25,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}